SESSION TYPE: New Insights into Idiopathic Pulmonary Fibrosis
PRESENTED ON: Sunday, October 21, 2012 at 01:15 PM - 02:45 PM
PURPOSE: To evaluate the efficacy and safety of Chinese herb on the treatment of Idiopathic Pulmonary Fibrosis (IPF)
METHODS: We performed a longitude cohort study to evaluate the efficacy and safety of Chinese herb on the treatment of IPF. Patients were diagnosed as IPF based on the diagnosis guideline of ATS and ERS. All patients meeting the diagnosis criteria and agreed to take only Chinese herb for the long-term management were enrolled in the study. The primary outcome was the long term survival after the enrollment into the study. The secondary outcome was the Quality of life assessed by St George's respiratory questionnaire (SGRQ) in one year follow-up.
RESULTS: A total of 30 patients were recruited into the study from January 2007 to December 2007. The baseline characteristic are of 65 (±10) years old, 16 males (53%), 10 patients(33%) present with smoking history. All patients were followed up till the end of 2011 and 14 patients survived. The median survival was 3.9 years. The score of SGRQ at one year follow-up decreased from baseline 61.17±17.72 to 55.45±17.46 (p=0.04). Diffusion capacity had kept almost the same level for the 12 months, and had no significant difference before and after one year follow-up (P>0.05). No significant adverse event was observed during the whole study period.
CONCLUSIONS: Chinese herb was safe and effective in the management of IPF patients. Chinese herb could improve patient's quality of life and increase patients' active capacity.
CLINICAL IMPLICATIONS: Alternative medicine should be considered in the management of IPF.
DISCLOSURE: The following authors have nothing to disclose: Hui Li, Shigang Liu, Zhiguo Liu, Lei Li, Yongjun Bian, Zaiya Jin, Guoqin Li
No Product/Research Disclosure InformationGuang An Men Hospital, China Academy of Chinese Medical Science, Beijing, China